Lv2
110 积分 2026-03-02 加入
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
1个月前
已完结
Autologous CD19/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease
1个月前
已完结
Successful Spontaneous Pregnancies and Healthy Neonates After Dual‐Target CAR –T Cell Therapy in Systemic Lupus Erythematosus
1个月前
已完结
Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap
1个月前
已完结
Cyclosporin a- versus tacrolimus-specific lesions in calcineurin inhibitor nephrotoxicity
1个月前
已完结
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
2个月前
已完结
Long-term Outcomes of Second Allogeneic Transplantation following CD7 CAR-T in Remission for T-cell Acute Lymphoblastic Leukemia or Lymphoma
2个月前
已完结
Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed/refractory acute myeloid leukemia
2个月前
已关闭
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
3个月前
已完结
Anti–CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE
3个月前
已完结
皖公网安备34019202002308
